Objective: To ascertain plasma levels of heat shock protein 90a (HSP90a) and squamous cell carcinoma antigen (SCC-Ag) and their diagnostic potential in cervical cancer. Methods: In a cross-sectional study, patients' cervical tissue samples were screened for high risk (HR) human papilloma virus (HPV) DNA and underwent a thinprep-liquid based cytology test (TCT). Plasma samples were analysed by enzyme-linked immunosorbent assay (ELISA) for HSP90 a and SCC-Ag levels. Results: Of the 295 women who underwent screening, 75 were healthy controls 75 (HR-HPV Àve TCT Àve ), 110 were HR-HPV þve , TCT Àve and 110 were HR-HPV þve TCT þve . There were significant differences between levels of HSP90a and SCC-Ag proteins across the patient groups with those positive for cervical cancer having the greatest levels of proteins compared with other groups. For patients with high grade SCC there was a significant correlation between levels of HSP90a and SCC-Ag. The area under the ROC curve for combined HSP90a*SCC-Ag was the largest compared with the single proteins. Using a cut-off value of 16.4 ng/ml to delineate cervical cancer diagnosis, the sensitivity and specificity of HSP90a*SCC-Ag were 90.3% and 95.1% respectively. Conclusion: Plasma HSP90a protein levels correlated well with SCC-Ag levels in patients with cervical cancer and the combination of HSP90a*SCC-Ag may be a useful diagnostic biomarker.
Introduction
Cervical cancer is one of the most common gynaecological malignancies and is the fourth leading cause of all cancer deaths in women. 1, 2 An epidemiological survey conducted in China over the period from 1998 to 2008, suggested that the incidence cervical cancer is increasing. 3 Although there are several potential causes of cervical cancer, human papilloma virus (HPV) infection is the main underlying cause, 4 and up to 14 high risk (HR) HPV genotypes have been implicated 5 Precancerous lesions usually take 10-20 years to develop into cervical cancer. 6 Accordingly, women who have received inadequate or no screening for cervical cancer may present with advanced stage disease. 2 Therefore, early diagnosis is critical for a good prognosis. Commonly used screening methods for cervical lesions include cervical cytology tests, human papillomavirus (HPV) detection and colposcopy examination. 1 However, the current screening techniques and strategies have many deficiencies. 1, 7 Consequently, there has been an interest in identifying markers that can complement standard pathological evaluations to identify the presence of cancer cells in cervical tissues. 7, 8 Among the different histological subtypes of cervical cancer, squamous cell carcinoma (SCC) accounts for 85-90% of all cervical cancer cases. 7 Studies have reported that elevated pre-treatment SCC-antigen (Ag) levels correlate with the stage of the disease, size of the tumour and depth of cervical stromal invasion. 7, 9 However, the detection of SCC-Ag alone has certain limitations. While serum levels of SCC-Ag may reflect response to therapy, 10 some studies have reported that the tumour marker has no prognostic value. 10, 11 Heat shock proteins (HSPs) are vital in the synthesis and stability of several signal transduction proteins and so have an important role in cell survival. 12 HSPs are classified according to their size and HSP90 has been investigated as a potential target in cancer therapy. 12 Two forms of HSP90 (HSP90a and HSP90b) are located in the cytoplasm. 13 HSP90a appears to respond to stress 14 whereas Hsp90b is involved in processes that maintain viability. 15 Studies have shown that expression level of HSP90a was associated with the occurrence and metastasis of cancer. 16, 17 Other studies have shown that HSP90a can act as a tumour marker in liver cancer 18 and lung cancer. 19, 20 This study was designed to assess and compare levels of HSP90a and SCC-Ag in plasma samples from patients who underwent screening for cervical cancer and explore if HSP90a had diagnostic applications.
Methods
For this cross-sectional study, tissue samples were obtained from women who underwent cervical cancer screening in the gynaecological outpatient department of the Third Clinical Medical College (Affiliated Tumour Hospital) of Xinjiang Medical University between April 2017 and May 2018.
HR-HPV DNA detection in combination with a thinprep-liquid based cytology test (TCT) was used as the screening method. 20 HPV DNA testing by the second-generation hybridization capture test (HC2) assay method was performed with the automated HC2 assay system according to the manufacturer's protocol. The samples were analysed for the presence of HR HPV types (i.e., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 . Samples were classified as HR HPV DNA positive if the ratio of the relative light unit (RLU) reading obtained from the luminometer to the mean value for the positive cutoff value (PC) was !1. For the TCT test, section preparation, and staining were performed according to the manufacturer's instructions. TCT positive samples were graded as follows: atypical squamous cells of undetermined significance (ASC-US); low-grade squamous intraepithelial lesion (LSIL); high-grade squamous intraepithelial lesion (HSIL) or carcinoma in situ; squamous cell carcinoma (SCC).
In accordance with the test results, patients were separated into three groups: a healthy control group (HR-HPV Àve, TCT Àve ); an infected group (HR-HPV þve , TCT Àve ); a cervical lesion group (HR-HPV þve TCT þve ). Colposcopic biopsy was performed in patients with HR-HPV þve and TCT (!ASC-US).
Blood samples from the patients were obtained in the morning after an overnight fast. The samples (2ml) were placed into tubes containing EDTA-K2 and centrifuged at 3000r/min for 10 minutes at room temperature. Plasma samples were stored until use at -20 degrees for less than 1 month, or frozen at -80 degrees for no more than 6 months.
Plasma levels of HSP90a were measured using a commercially available enzymelinked immunosorbent assay (ELISA) kit (Yantai Protgen Biotechnology Development Co., Ltd, Yantai, China), according to the manufacturer's protocols. Optical density was measured using a spectrophotometer at 450 nm. The amount of protein in each sample was calculated according to a standard curve of optical density values and Curve Expert 1.3 software was used to analyse the data. SCC Ag concentrations were determined using an i2000SR full-automatic chemiluminescence immunoassay analyzer (Abbott Laboratories, Abbott Park, IL, USA). All analyses were performed according to the manufacturers' instructions.
All patients provided written informed consent before participating in the study and the study protocol was approved by the Ethics Committee of the Third Clinical Medical College (Affiliated Tumor Hospital) of Xinjiang Medical University.
Statistical analyses
Data were analysed using the IBM Statistical Package for Social Sciences (SPSS V R ) for Windows V R release 21.0 (IBM Corp., released 2012; Armonk, NY, USA) and a P-value <0.05 was considered to indicate statistical significance.
According to results from the Kolmogorov-Smirnov (K-S) test, the data were skewed and so nonparametric tests (Wilcoxon, rank sum test) were used to compare differences. ROCKIT software (ROCKIT 0.9B Beta Version, Charles E. Metz, University of Chicago) was used to generate Receiver operating characteristic (ROC) curves to compare predictive sensitivity, specificity, and the area under the curve (AUC) with 95% CI.
The correlation between SCC-Ag and HSP90a according to TCT results was examined using Spearman's correlation test. Measures of diagnostic accuracy (i.e., Youden index, Likelihood ratio (LR), positive predictive value [PPV] and negative predictive value [NPV]) were calculated. 21
Results
Between April 2017 and May 2018, 295 women (median age 52 years, range 25 to 80 years) were screened for cervical lesions in our department. According to test results, 75 women were in the HR-HPV Àve TCT Àve group (i.e., heathy controls), 110 were in the HR-HPV þve , TCT Àve group and 110 were in the HR-HPV þve TCT þve group (Table 1) . Therefore, 110 patients had a colposcopic biopsy to confirm positive results. Patients' plasma levels of SCC-Ag and HSP90a were statistically significantly different across the three patient groups (Table 1; Figure 1 ) In addition, HSP90a levels were statistically significantly different between patient groups.
According to TCT results, 29 patients had ASC-US, 60 patients had LSIL, 21 patients had HSIL and none had SCC ( Table 2) . Patients in the ASC-US group, showed no correlation between HSP90a and SCC-Ag results. However, for patients in the LSIL and HSIL groups, statistically significant correlations were detected for plasma HSP90a and SCC-Ag levels; the most significant correlation between proteins was observed in the HSIL group (Table 2) .
Area under the ROC curves, cut off values for cervical cancer diagnosis, sensitivities and specificities for plasma SCC-Ag, HSP90a and HSP90a*SCCAg were determined ( Figure 2 , Table 3 ). Using a cut-off value of 16.4 ng/ml to delineate cervical cancer diagnosis, compared with the other groups, the largest AUC and highest sensitivity and specificity were for the combined HSP90a*SCC-Ag group. Therefore, this combination of proteins may have more advantages as a diagnostic indicator of cervical lesions over the proteins alone.
Combining data from the ROC curve analysis with other measures of diagnostic accuracy, HSP90a*SCCAg appears to be more discriminative than the proteins alone (Table 4 ). 
Discussion
Although cervical cancer is preventable, over the past decade, the incidence and mortality rates associated with the disease have increased in China. 3 Therefore, there is a need to establish a comprehensive prevention screening program. Currently, cervical smear tests, liquid-based cytology and colposcopy examinations are commonly used to diagnose the disease. However, due to inadequate screening programs, a diagnosis of cervical cancer may be missed. 2 Therefore, finding new and easy methods for early detection of the cancer is imperative. Tumour markers are proteins or enzymes secreted by tumour cells or host cells during the process of carcinogenesis. Indeed, detecting tumour markers in the blood can be a critical method for the early tumour detection. 7 Our study found that there were significant differences between levels of HSP90a and SCC-Ag across the patient groups with those positive for cervical cancer having the greatest levels of proteins compared with other patient groups and controls. In addition, we found that there was a significant correlation between SCC-Ag and HSP90a in patients with cervical cancer and the association between the two proteins increased as the severity of the cancer increased. Using ROC analysis, combined HSP90a*SCC-Ag had the largest AUC compared with the single proteins. Other measures of diagnostic accuracy (i.e., Youden's; index, likelihood ratios and predictive values) tended to confirm the discriminatory potential of HSP90a*SCC-Ag. These results suggest that HSP90a*SCC-Ag has more advantages and clinical implications in the diagnosis of cervical cancer lesions than either SCC-Ag or HSP90a alone. Limitations of the study included the small sample size and the crosssectional and single centre design. Further, large scale, prospective multicentre studies are required to confirm our results. In summary, this study found that by comparison with controls, plasma samples from women with cervical cancer contained significantly high levels of HSP90a. Furthermore, compared with HSP90a or SCC-Ag, the combination of HSP90a* SCC-Ag had a better diagnostic potential as a biomarker for cervical lesions. The addition of HSP90a*SCC-Ag assessment to HR-HPV DNA detection and cytology could possibly result in a more robust diagnostic test for early detection of cervical cancer and lead to reductions in missed diagnosis and mortality from the disease.
